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another vasoactive and proinflammatory peptide, from its
inactive precursor angiotensin I.
A limitation of the study by Strbian and colleagues10
with respect to future clinical applications is that the MC
stabilizer cromoglycate had to be administered directly
into the cerebrospinal fluid via the intraventricular route
because this substance does not cross the blood-brain
barrier. This approach is not applicable under clinical
conditions in which the systemic (preferably intravenous)
delivery of pharmacological compounds is desirable. Fur-
thermore, Strbian et al investigated a model of mechani-
cally induced ischemia-reperfusion injury, not of cerebral
thromboembolism/thrombolysis, which would be clinically
more relevant. Thus, proof-of-concept studies are required
to determine whether the benefits of MC stabilization can
be applied to thromboembolic stroke.
We propose that the bench-to-bedside translation of
findings from experimental animals to human patients is
a priority issue for the future, given that reperfusion
therapies have not achieved implementation in acute is-
chemic stroke similar to that in acute myocardial infarc-
tion. Even in large university hospitals with excellent
infrastructures, thrombolysis rates hardly exceed 5% to
10% of patients with stroke admitted to stroke units. These
low thrombolysis rates in stroke can be attributed to local
bleeding complications, which may result at least in part
from secondary reperfusion injury triggered by tPA.
On the pathophysiological level, the striking parallels
between the role of MCs in inflammatory responses in the
brain and atherosclerotic plaque rupture deserve our attention.
Along this line, the role of allergen-induced or IgE- or
MC-mediated immune responses in atherogenesis, thrombo-
sis, or reperfusion injury would be a promising research
avenue. The data by Strbian and colleagues10 suggest that IgE
receptor blockade might mimic the beneficial effects of
pharmacological MC stabilizers in the stroke brain. A better
understanding of the mechanisms underlying tPA-induced
reperfusion injury may provide valuable tools to decrease the
detrimental effects of tPA, thereby increasing its therapeutic
potential in stroke patients. Such insights will cross-fertilize
research concepts in the cardiovascular field.
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Effects of tPA in the ischemic tissue
mediated by MCs. tPA promotes MC
degranulation after acute ischemic stroke
in both the reperfused brain parenchyma
and vulnerable atherosclerotic plaques,
leading to the release of various media-
tors such as the vasoactive peptides his-
tamine and bradykinin, the anticoagulant
heparin, various cytokines and chemo-
kines, basic fibroblast growth factor
(bFGF), and the proteases tryptase and
chymase. These mediators exert a vari-
ety of actions in the reperfused tissue
affecting vasomotion, vascular perme-
ability, inflammation, thrombosis, athero-
genesis, and plaque rupture, all of which
may increase the susceptibility for sec-
ondary injury and brain hemorrhage.
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